162 related articles for article (PubMed ID: 38010696)
1. Neuro-Ophthalmic Adverse Events of COVID-19 Infection and Vaccines: A Nationwide Cohort Study.
Han JY; Kim S; Han J; Kim SS; Han SH; Lee SW; Kim YJ
Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):37. PubMed ID: 38010696
[TBL] [Abstract][Full Text] [Related]
2. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
[TBL] [Abstract][Full Text] [Related]
4. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
[TBL] [Abstract][Full Text] [Related]
5. Miller Fisher syndrome following COVID-19 vaccines: A scoping review.
Kim JE; Yoon BA; Kim YH; Kim JK; Bae JS
Acta Neurol Scand; 2022 Nov; 146(5):604-609. PubMed ID: 35938305
[TBL] [Abstract][Full Text] [Related]
6. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Min YG; Hong YH; Song TJ
J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
[TBL] [Abstract][Full Text] [Related]
7. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S
Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559
[TBL] [Abstract][Full Text] [Related]
8. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database.
Keh RYS; Scanlon S; Datta-Nemdharry P; Donegan K; Cavanagh S; Foster M; Skelland D; Palmer J; Machado PM; Keddie S; Carr AS; Lunn MP;
Brain; 2023 Feb; 146(2):739-748. PubMed ID: 35180300
[TBL] [Abstract][Full Text] [Related]
10. Optic Neuritis and Cranial Neuropathies Diagnosis Rates before Coronavirus Disease 2019, in the Initial Pandemic Phase, and Post-Vaccine Introduction.
Zhao D; Li X; Carey AR; Henderson AD;
Ophthalmology; 2024 Jan; 131(1):78-86. PubMed ID: 37634758
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies.
Alijanzadeh D; Soltani A; Afra F; Salmanpour F; Loghman AH; Samieefar N; Rezaei N
BMC Neurol; 2023 Sep; 23(1):332. PubMed ID: 37735648
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
13. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
[TBL] [Abstract][Full Text] [Related]
15. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: Case report and scope review.
Liang H; Cao Y; Zhong W; Ma Z; Liu J; Chen H
Hum Vaccin Immunother; 2022 Nov; 18(6):2125753. PubMed ID: 36315834
[TBL] [Abstract][Full Text] [Related]
16. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
[TBL] [Abstract][Full Text] [Related]
17. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
Whiteley WN; Ip S; Cooper JA; Bolton T; Keene S; Walker V; Denholm R; Akbari A; Omigie E; Hollings S; Di Angelantonio E; Denaxas S; Wood A; Sterne JAC; Sudlow C;
PLoS Med; 2022 Feb; 19(2):e1003926. PubMed ID: 35192597
[TBL] [Abstract][Full Text] [Related]
18. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM;
Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917
[TBL] [Abstract][Full Text] [Related]
19. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
Wan EYF; Chui CSL; Lai FTT; Chan EWY; Li X; Yan VKC; Gao L; Yu Q; Lam ICH; Chun RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Leung GM; Wong ICK
Lancet Infect Dis; 2022 Jan; 22(1):64-72. PubMed ID: 34411532
[TBL] [Abstract][Full Text] [Related]
20. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom.
Otero-Losada M; Petrovsky N; Alami A; Crispo JA; Mattison D; Capani F; Goetz C; Krewski D; Perez-Lloret S
Expert Opin Drug Saf; 2023 Apr; 22(4):343-349. PubMed ID: 36043937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
